Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Terrance D. Barrett, Heather L. Palomino, Theresa I. Brondstetter, Kimon C. Kanelakis, Xiaodong Wu, Peter V. Haug, Wen Yan, Andrew Young, Hong Hua, Juliet C. Hart, Da-Thao Tran, Hariharan Venkatesan, Mark D. Rosen, Hillary M. Peltier, Kia Sepassi, Michele C. Rizzolio, Scott D. Bembenek, Tara Mirzadegan, Michael H. Rabinowitz and Nigel P. Shankley
Molecular Pharmacology June 2011, 79 (6) 910-920; DOI: https://doi.org/10.1124/mol.110.070508
Terrance D. Barrett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather L. Palomino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa I. Brondstetter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimon C. Kanelakis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaodong Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter V. Haug
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen Yan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Young
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Hua
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet C. Hart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Da-Thao Tran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hariharan Venkatesan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark D. Rosen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hillary M. Peltier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kia Sepassi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele C. Rizzolio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott D. Bembenek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tara Mirzadegan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H. Rabinowitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nigel P. Shankley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) enzymes represent novel targets for the treatment of anemia, ulcerative colitis, and ischemic and metabolic disease inter alia. We have identified a novel small-molecule inhibitor of PHD, 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), through structure-based drug design methods. The pharmacology of JNJ-42041935 was investigated in enzyme, cellular, and whole-animal systems and was compared with other compounds described in the literature as PHD inhibitors. JNJ-42041935, was a potent (pKI = 7.3–7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes. In addition, JNJ-42041935 was used to compare the effect of selective inhibition of PHD to intermittent, high doses (50 μg/kg i.p.) of an exogenous erythropoietin receptor agonist in an inflammation-induced anemia model in rats. JNJ-42041935 (100 μmol/kg, once a day for 14 days) was effective in reversing inflammation-induced anemia, whereas erythropoietin had no effect. The results demonstrate that JNJ-42041935 is a new pharmacological tool, which can be used to investigate PHD inhibition and demonstrate that PHD inhibitors offer great promise for the treatment of inflammation-induced anemia.

Footnotes

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    doi:10.1124/mol.110.070508.

  • ABBREVIATIONS:

    HIF
    hypoxia-inducible factor
    PHD
    prolyl-4-hydroxylase
    2-OG
    2-oxoglutarate
    rhEPO
    recombinant human erythropoietin
    DMOG
    dimethyloxalylglycine
    3,4-EDHB
    ethyl-3,4-dihydroxybenzoate
    JNJ-42041935
    1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid
    FIH
    factor-inhibiting hypoxia-inducible factor
    PGPS
    peptidoglycan-polysaccharide polymers
    MCV
    mean corpuscular volume
    MCH
    mean cell hemoglobin.

  • Received December 10, 2010.
  • Accepted March 3, 2011.
  • Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 79 (6)
Molecular Pharmacology
Vol. 79, Issue 6
1 Jun 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Research ArticleArticle

Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Terrance D. Barrett, Heather L. Palomino, Theresa I. Brondstetter, Kimon C. Kanelakis, Xiaodong Wu, Peter V. Haug, Wen Yan, Andrew Young, Hong Hua, Juliet C. Hart, Da-Thao Tran, Hariharan Venkatesan, Mark D. Rosen, Hillary M. Peltier, Kia Sepassi, Michele C. Rizzolio, Scott D. Bembenek, Tara Mirzadegan, Michael H. Rabinowitz and Nigel P. Shankley
Molecular Pharmacology June 1, 2011, 79 (6) 910-920; DOI: https://doi.org/10.1124/mol.110.070508

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Terrance D. Barrett, Heather L. Palomino, Theresa I. Brondstetter, Kimon C. Kanelakis, Xiaodong Wu, Peter V. Haug, Wen Yan, Andrew Young, Hong Hua, Juliet C. Hart, Da-Thao Tran, Hariharan Venkatesan, Mark D. Rosen, Hillary M. Peltier, Kia Sepassi, Michele C. Rizzolio, Scott D. Bembenek, Tara Mirzadegan, Michael H. Rabinowitz and Nigel P. Shankley
Molecular Pharmacology June 1, 2011, 79 (6) 910-920; DOI: https://doi.org/10.1124/mol.110.070508
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Protocol-dependent differences in IC50 values measured in hERG assays occur in a predictable way and can be used to quantify state preference of drug binding.
  • Statins perturb Gβγ signaling and cell behaviors in a Gγ subtype dependent manner
  • A comparison of the ability of Leu8- and Pro8-oxytocin to regulate intracellular Ca2+ and Ca2+-activated K+ channels at human and marmoset oxytocin receptors.
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics